0001628280-16-020505.txt : 20161101 0001628280-16-020505.hdr.sgml : 20161101 20161101120450 ACCESSION NUMBER: 0001628280-16-020505 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161028 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20161101 DATE AS OF CHANGE: 20161101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHAMPIONS ONCOLOGY, INC. CENTRAL INDEX KEY: 0000771856 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 521401755 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11504 FILM NUMBER: 161963824 BUSINESS ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 619 CITY: BALTIMORE STATE: MD ZIP: 21205 BUSINESS PHONE: 410-369-0365 MAIL ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 619 CITY: BALTIMORE STATE: MD ZIP: 21205 FORMER COMPANY: FORMER CONFORMED NAME: CHAMPIONS BIOTECHNOLOGY, INC. DATE OF NAME CHANGE: 20070220 FORMER COMPANY: FORMER CONFORMED NAME: CHAMPIONS SPORTS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: INTERNATIONAL GROUP INC DATE OF NAME CHANGE: 19860319 8-K 1 csbr8-k10252016.htm 8-K Document


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________
 
FORM 8-K
 
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): October 28, 2016
 
CHAMPIONS ONCOLOGY, INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware
001-11504
52-1401755
(State or Other Jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
 
Identification No.)
 
1 University Plaza, Suite 307, Hackensack, New Jersey 07601
(Address of Principal Executive Offices) (Zip Code)
 
Registrant’s telephone number, including area code: (201) 808-8400
 
Not applicable
(Former Name or Former Address if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
 
 
 
 
 





INFORMATION TO BE INCLUDED IN THE REPORT
 
 
Item 5.02.
Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers.
 
On October 28, 2016, Champions Oncology, Inc. (the “Company”) extended the initial employment agreements dated November 5, 2013 between the Company and each of Joel Ackerman, Chief Executive Officer, and Ronnie Morris, President. The extensions are for 1 year and provide that each of Mr. Ackerman and Mr. Morris shall be compensated $325,000 in the form of stock options. All other terms and conditions of the agreements remain.







SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
CHAMPIONS ONCOLOGY, INC.
 
 
(Registrant)
 
 
 
 
Date: November 1, 2016
 
By:
/s/ Joel Ackerman
 
 
 
Joel Ackerman
 
 
 
Chief Executive Officer